How India Exports Topotecan to the World

In the United States, the Food and Drug Administration (FDA) has approved multiple Abbreviated New Drug Applications (ANDAs) for topotecan, facilitating the availability of generic versions. For instance, Sandoz, Inc. received approval for topotecan for injection (NDA 200199) on February 25, 2011, and Teva Pharmaceuticals USA obtained approval for topotecan injection (NDA 022453) on December 20, 2012. These approvals indicate a competitive market landscape for topotecan in the U.S. Additionally, as of March 21, 2024, the FDA granted orphan drug designation to topotecan liposome injection for the treatment of Merkel Cell Carcinoma, highlighting ongoing developments in its therapeutic applications.

Within the European Union, topotecan has been subject to various regulatory actions. The European Medicines Agency (EMA) granted marketing authorizations to several generic versions, such as Topotecan Actavis on July 24, 2009. However, this authorization was withdrawn on January 15, 2019, at the request of the marketing authorization holder, Actavis Group PTC ehf, due to commercial reasons. Similarly, Topotecan Eagle's authorization was withdrawn on October 2, 2014, upon the request of Eagle Laboratories Ltd. These withdrawals reflect the dynamic nature of the European pharmaceutical market and the strategic decisions of marketing authorization holders. (ema.europa.eu)

Topotecan is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in cancer treatment protocols. The drug is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different regions.

In India, topotecan is classified under Schedule H of the Drugs and Cosmetics Rules, 1945, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of the latest available data, topotecan is not listed under the Drugs (Prices Control) Order (DPCO), suggesting that its price is not subject to government-mandated ceilings. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations.

The primary patents for topotecan have expired, leading to increased generic competition globally. This has resulted in a more competitive market, influencing pricing and availability. Manufacturers exporting from India must navigate this competitive landscape by ensuring compliance with international regulatory standards and maintaining high-quality production to sustain market share.

In March 2024, the FDA granted orphan drug designation to topotecan liposome injection for the treatment of Merkel Cell Carcinoma, indicating potential new therapeutic applications for the drug.

In January 2019, the European Commission withdrew the marketing authorization for Topotecan Actavis at the request of the marketing authorization holder, Actavis Group PTC ehf, due to commercial reasons. (ema.europa.eu)

In October 2014, the European Commission withdrew the marketing authorization for Topotecan Eagle at the request of the marketing authorization holder, Eagle Laboratories Ltd, also due to commercial reasons. (ema.europa.eu)

These developments reflect the evolving regulatory and commercial landscape for topotecan, emphasizing the importance for exporters to stay informed about international regulatory changes and market dynamics.

India's pharmaceutical industry, including the production of Topotecan, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of these essential components are sourced from Chinese manufacturers. This dependency exposes the supply chain to significant risks, particularly during geopolitical tensions or trade disruptions.

In recent years, efforts have been made to reduce this reliance. In October 2024, under the Production Linked Incentive (PLI) scheme, India inaugurated two greenfield plants aimed at manufacturing critical molecules like Penicillin G and Clavulanic Acid, which had not been produced domestically for over two decades. These initiatives are expected to halve India's import dependence on key pharmaceutical ingredients. However, the transition to self-sufficiency is gradual, and the industry remains vulnerable to external supply shocks in the interim.

The export data for Topotecan reveals a high supplier concentration, with the top five exporters accounting for 97.2% of total exports. Notably, INTAS PHARMACEUTICALS LIMITED dominates with an 87.5% share, amounting to $3.3 million USD. This heavy reliance on a single supplier poses a significant risk; any operational disruptions at INTAS could severely impact global Topotecan availability.

To mitigate such risks, the Indian government has implemented the PLI scheme to encourage diversification and bolster domestic API production. While these measures are promising, their effectiveness in reducing supplier concentration will take time to materialize. In the short term, the Topotecan supply chain remains susceptible to disruptions stemming from this high dependency on a single exporter.

Recent geopolitical events have further strained the pharmaceutical supply chain. In March 2026, the closure of the Strait of Hormuz amid escalating conflicts led to significant disruptions in global trade routes. This blockade halted maritime traffic, affecting the transportation of essential goods, including pharmaceuticals. (lemonde.fr) Additionally, tensions in the Red Sea and the Suez Canal have forced shipping companies to reroute vessels around the Cape of Good Hope, adding approximately 10 to 14 days to transit times and increasing shipping costs.

These disruptions have cascading effects on the pharmaceutical industry, leading to delays in API deliveries and increased production costs. The U.S. Food and Drug Administration (FDA) has issued alerts regarding potential drug shortages resulting from these logistical challenges. Such geopolitical instabilities underscore the fragility of the current supply chain and the urgent need for strategic risk mitigation.

• Diversify Supplier Base: Encourage partnerships with multiple API and KSM suppliers across different regions to reduce dependency on a single source.

• Enhance Domestic Production: Accelerate initiatives under the PLI scheme to boost local manufacturing of critical pharmaceutical ingredients, thereby decreasing reliance on imports.

• Strengthen Inventory Management: Maintain strategic stockpiles of essential APIs and finished products to buffer against supply chain disruptions.

• Develop Alternative Logistics Routes: Invest in and establish alternative shipping and transportation routes to mitigate the impact of geopolitical tensions on existing pathways.

• Implement Robust Risk Assessment Protocols: Regularly assess and update risk management strategies to proactively address potential supply chain vulnerabilities.

RISK_LEVEL: HIGH